Clinical attribute-based risk matrix for prognostication in immunotherapy-treated non-small cell lung cancer
Biomarkers used to guide immunotherapy in non-small cell lung cancer (NSCLC) are invasive, variably available, and insufficient to capture clinical and regional heterogeneity, leaving many patients inadequately stratified for prognosis. We develop a clinical attribute–based framework that leverages routinely collected...